Table 2.
Univariable analysis of the treatment of women with severe hypertensive disorders during childbirth, comparison of relative risk of outcomes during the ninth to 12th months of the intervention (October 1, 2015, to January 31, 2016) compared with during the baseline period (October 1, 2014, to January 31, 2015).a
| Characteristic | At baseline (n=188) | At 9–12 intervention months (n=196) | P value | RR (95% CI) |
|---|---|---|---|---|
| Antihypertensive treatment | ||||
| All women with severe hypertensionb | 184 | 193 | ||
| Hydralazine or nifedipine administered | 86 (46.7) | 124 (64.2) | 1.37 (1.14–1.66) | |
| Anticonvulsant treatment | ||||
| Women with urine protein ≥2 or eclampsiac | 121 | 144 | ||
| MgSO4 treatment initiated | 110 (90.9) | 127 (88.2) | 0.97 (0.89–1.05) | |
| Women receiving MgSO4 | 110 | 127 | ||
| Patellar reflexes and respiratory rate at least once | 20 (18.2) | 44 (34.6) | 1.91 (1.20–3.03) | |
| Labor progression | ||||
| All women with the required date and time recorded: | 173 | 189 | ||
| Time from inclusion criteria recorded till delivery, min | 390 (161–790) | 457 (225–745) | 0.356d | |
| All study women | 188 | 196 | ||
| Partograph action line crossed (prolonged first stage) | 22 (11.7) | 22 (11.2) | 0.96 (0.55–1.67) | |
| Induction of labore | 48 (25.5) | 75 (38.3) | 1.50 (1.11–2.03) | |
| Oxytocin for augmentation in active phase of laborf | 45 (23.9) | 36 (18.4) | 0.77 (0.52–1.13) | |
Abbreviations: CI, confidence interval; MgSO4, magnesium sulfate; RR, relative risk.
Values are given as absolute number, number (percentage), or median (interquartile range), unless indicated otherwise.
Diagnostic criteria for severe hypertension applied: systolic BP ≥160 mm Hg and/or diastolic BP ≥110 mm Hg.
Diagnostic criteria for severe pre‐eclampsia/eclampsia applied: severe hypertension on at least one reading and urine protein ≥2, or eclampsia/convulsions described (owing to poor data quality, women without severe hypertension or eclampsia, but fulfilling the WHO criteria of severe pre‐eclampsia due to symptoms of organ failure could not be identified). For an additional 28/188 (15%) women at baseline and 12/193 (6%) during the intervention, urine dipstick was not performed.
Mann‐Whitney test for difference.
One woman was induced by balloon catheter; all others were induced by misoprostol with or without subsequent oxytocin.
Women were excluded if induced. For 11/45 (24%) and 7/36 (19%), respectively, membranes were still intact when starting oxytocin augmentation (RR 0.80, 95% CI 0.34–1.84).